Response to 'Mortality risk for patients receiving hemodiafiltration versus hemodialysis' [4]

Kidney International

Volumn 70, Issue 8, 2006, Pages 1524-1525

  Canaud, B ^a   Bragg Gresham, J L ^a   Marshall, M R ^a   Desmeules, S ^a   Gillespie, B W ^a   Depner, T ^a   Klassen, P ^a   Port, F K ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AEDES; BIOCOMPATIBILITY; CLINICAL PRACTICE; COMORBIDITY; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INTERNATIONAL COOPERATION; KIDNEY FAILURE; LETTER; MOLECULAR MODEL; ONLINE ANALYSIS; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 33749528186     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001771     Document Type: Letter

References (4)

1. Jirka T, Cesare S, Di Benedetto A et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis. Kidney Int 2006.
2. Canaud B, Bragg-Gresham JL, Marshall MR et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69: 2087-2093.
3. Canaud B, Morena M, Cristol JP, Krieter D. Beta2-microglobulin, a uremic toxin with a double meaning. Kidney Int 2006; 69: 1297-1299.
4. Canaud B, Morena M, Leray-Moragues H, Chalabi L, Cristol JP. Overview of clinical studies in hemodiafiltration: what do we need now? Hemodial Int 2006; 10(Suppl 1): S5-S12.